XNAS:BGMD BG Medicine Inc Insider Activity 4 Filing - 8/20/2012

Effective Date 8/20/2012

XNAS:BGMD (BG Medicine Inc): Fair Value Estimate
Premium
XNAS:BGMD (BG Medicine Inc): Consider Buying
Premium
XNAS:BGMD (BG Medicine Inc): Consider Selling
Premium
XNAS:BGMD (BG Medicine Inc): Fair Value Uncertainty
Premium
XNAS:BGMD (BG Medicine Inc): Economic Moat
Premium
XNAS:BGMD (BG Medicine Inc): Stewardship
Premium
 
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
AFEYAN NOUBAR
  2. Issuer Name and Ticker or Trading Symbol
BG Medicine, Inc. [BGMD]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O FLAGSHIP VENTURES, ONE MEMORIAL DRIVE, 7TH FLOOR
3. Date of Earliest Transaction (Month/Day/Year)
08/20/2012
(Street)

CAMBRIDGE, MA 02142
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/20/2012   X   2,353 A $0.03 278,953 I By NewcoGen-Elan LLC(1)
Common Stock 08/20/2012   S(2)   13 D $5.83(3) 278,940 I By NewcoGen-Elan LLC(1)
Common Stock 08/20/2012   X   6,422 A $0.02 285,362 I By NewcoGen-Elan LLC(1)
Common Stock 08/20/2012   S(4)   23 D $5.83(3) 285,339 I By NewcoGen-Elan LLC(1)
Common Stock 08/20/2012   X   6,422 A $0.02 291,761 I By NewcoGen-Elan LLC(1)
Common Stock 08/20/2012   S(5)   23 D $5.83(3) 291,738 I By NewcoGen-Elan LLC(1)
Common Stock 08/20/2012   X   6,422 A $0.02 298,160 I By NewcoGen-Elan LLC(1)
Common Stock 08/20/2012   S(6)   23 D $5.83(3) 298,137 I By NewcoGen-Elan LLC(1)
Common Stock 08/21/2012   J(7)   298,137 D $ 0 0 I By NewcoGen-Elan LLC(1)
Common Stock               526,560 I By NewcoGen Equity Investors LLC(1)
Common Stock               92,294 I By NewcoGen-Long Reign Holding LLC(1)
Common Stock               92,126 I By ST NewcoGen LLC(1)
Common Stock               140,013 I By AGTC Advisors Fund, L.P.(1)
Common Stock               2,351,447 I By Applied Genomic Technology Capital Fund, L.P.(1)
Common Stock               2,184,800 I By NewcoGen Group LLC(1)
Common Stock               4,232 I By OneLiberty Advisors Fund 2000 L.P.(8)
Common Stock               80,424 I By OneLiberty Ventures 2000 L.P.(8)
Common Stock               714,286 I By Flagship Ventures Fund 2007, L.P.(9)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant to Purchase Common Stock (right to buy) $0.03 08/20/2012   X     2,353   (10) 07/10/2016 Common Stock 2,353 $ 0 0 I By NewcoGen-Elan LLC(1)
Warrant to Purchase Common Stock (right to buy) $0.02 08/20/2012   X     6,422   (10) 03/30/2020 Common Stock 6,422 $ 0 0 I By NewcoGen-Elan LLC(1)
Warrant to Purchase Common Stock (right to buy) $0.02 08/20/2012   X     6,422   (10) 09/27/2020 Common Stock 6,422 $ 0 0 I By NewcoGen-Elan LLC(1)
Warrant to Purchase Common Stock (right to buy) $0.02 08/20/2012   X     6,422   (10) 11/04/2020 Common Stock 6,422 $ 0 0 I By NewcoGen-Elan LLC(1)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
AFEYAN NOUBAR
C/O FLAGSHIP VENTURES
ONE MEMORIAL DRIVE, 7TH FLOOR
CAMBRIDGE, MA 02142
  X   X    
NewcoGen Elan LLC
C/O FLAGSHIP VENTURES
ONE MEMORIAL DRIVE, 7TH FLOOR
CAMBRIDGE, MA 02142
    X    
KANIA EDWIN M JR
C/O FLAGSHIP VENTURES
ONE MEMORIAL DRIVE, 7TH FLOOR
CAMBRIDGE, MA 02142
    X    
Flagship Ventures Management, Inc.
C/O FLAGSHIP VENTURES
ONE MEMORIAL DRIVE, 7TH FLOOR
CAMBRIDGE, MA 02142
    X    
NewcoGen Group, Inc.
C/O FLAGSHIP VENTURES
ONE MEMORIAL DRIVE, 7TH FLOOR
CAMBRIDGE, MA 02142
    X    

Signatures

 /s/ John P. Condon, Attorney-in-fact for Noubar Afeyan   08/22/2012
** Signature of Reporting Person Date

 /s/ John P. Condon, Attorney-in-fact for NewcoGen-Elan LLC   08/22/2012
** Signature of Reporting Person Date

 /s/ John P. Condon, Attorney-in-fact for Edwin M. Kania, Jr.   08/22/2012
** Signature of Reporting Person Date

 /s/ John P. Condon, Attorney-in-fact for Flagship Ventures Management, Inc.   08/22/2012
** Signature of Reporting Person Date

 /s/ John P. Condon, Attorney-in-fact for NewcoGen Group, Inc.   08/22/2012
** Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) NewcoGen Group, Inc. ("NG") is the manager of each of NewcoGen Group LLC ("NGG"), NewcoGen Equity Investors LLC ("NEI"), NewcoGen-Elan LLC ("NGE"), NewcoGen-Long Reign Holding LLC ("NGLRH") and ST NewcoGen LLC ("STN", and together with NGG, NEI, NGE and NGLRH, the "NewcoGen Funds"). NG is also the general partner of AGTC Partners, L.P., which is the general partner of AGTC Advisors Fund, L.P. ("AGTCA") and Applied Genomic Technology Capital Fund L.P. ("AGTCF", and together with AGTCA, the "AGTC Funds"). NG is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship"). Noubar Afeyan and Edwin M. Kania, Jr. are directors of Flagship and may be deemed to beneficially own the securities held by the NewcoGen Funds and the AGTC Funds. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.
(2) On August 20, 2012, NGE exercised a warrant to purchase 2,353 shares of Common Stock for $0.03 per share. NGE exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 13 of the warrant shares to pay the exercise price and issuing to NGE the remaining 2,340 shares.
(3) The price reflects the average of the closing prices of the Common Stock over the five day period prior to the exercise date.
(4) On August 20, 2012, NGE exercised a warrant to purchase 6,422 shares of Common Stock for $0.02 per share. NGE exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 23 of the warrant shares to pay the exercise price and issuing to NGE the remaining 6,399 shares.
(5) On August 20, 2012, NGE exercised a warrant to purchase 6,422 shares of Common Stock for $0.02 per share. NGE exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 23 of the warrant shares to pay the exercise price and issuing to NGE the remaining 6,399 shares.
(6) On August 20, 2012, NGE exercised a warrant to purchase 6,422 shares of Common Stock for $0.02 per share. NGE exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 23 of the warrant shares to pay the exercise price and issuing to NGE the remaining 6,399 shares.
(7) In addition to the cashless exercises of the warrants reported above, this Form 4 is being filed to report an in-kind distribution for no consideration by NGE to its sole member. The beneficial ownership of the entities named in this Form 4, other than the Reporting Persons filing this Form 4, did not change as a result of this transaction.
(8) Noubar Afeyan and Edwin M. Kania, Jr. are managing members of OneLiberty Partners 2000, LLC, which is the general partner of OneLiberty Advisors Fund 2000 L.P. ("OLA") and OneLiberty Ventures 2000 L.P. ("OLV"), and may be deemed to beneficially own the securities held by OLA and OLV. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.
(9) Noubar Afeyan and Edwin M. Kania, Jr. are managers of Flagship Ventures 2007 General Partner, LLC, which is the general partner of Flagship Ventures Fund 2007, L.P., and may be deemed to beneficially own the securities held by Flagship Ventures Fund 2007, L.P. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.
(10) This warrant is immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

XNAS:BGMD BG Medicine Inc Insider Activity 4 Filling

BG Medicine Inc XNAS:BGMD Stock - Get Insider Activity SEC Filing of BG Medicine Inc XNAS:BGMD stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

Content Partners
XNAS:BGMD BG Medicine Inc Insider Activity 4 Filing - 8/20/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: XNAS:BGMD BG Medicine Inc Insider Activity 4 Filing - 6/7/2012  |  Next: XNAS:BGMD BG Medicine Inc Insider Activity 4 Filing - 8/8/2012